Top

Published in:

01-07-2016 | Original Article

Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer

Authors: Jun Gu, Jie Chen, Jian Feng, Yifei Liu, Qun Xue, Guoxin Mao, Ling Gai, Xiaoning Lu, Rui Zhang, Jialin Cheng, Yanxia Hu, Mengting Shao, Hong Shen, Jianan Huang

Published in: Tumor Biology | Issue 7/2016

Abstract

Non-small cell lung cancer (NSCLC) is the major cause of cancer-related lethality among human cancer patients globally, and the poor prognosis of this cancer is mainly explained by metastasis, so it is essential to find out the molecule mechanisms and a novel therapeutic for NSCLC. A disintegrin and metalloprotease with thrombospondin motif 5 (ADAMTS5) belongs to the protease family. It has been reported to participate in tumor migration and invasion. In this study, we showed that the expression of ADAMTS5 was higher in lung cancer tissues by Western blot. The immunohistochemistry analysis was performed in 140 NSCLC cases, and the result indicated that ADAMTS5 was significantly associated with clinical pathologic variables. The Kaplan–Meier curve showed that the high expression of ADAMTS5 was related to poor prognosis of lung cancer patients. Wound healing assays and transwell migration assays revealed that the high expression of ADAMTS5 promoted the migration and invasion of NSCLC. In a word, our findings suggest that ADAMTS5 can regulate the migration and invasion of NSCLC and it may be a useful target of therapy in NSCLC.

Bender E. Epidemiology: the dominant malignancy. Nature. 2014;513(7517):S2–3.CrossRefPubMed

Ji L et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 2013;8(5), e63404.CrossRefPubMedPubMedCentral

Arola J et al. p53 and Ki67 in adrenocortical tumors. Endocr Res. 2000;26(4):861–5.CrossRefPubMed

Siegel R et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMed

Liu SV, Giaccone G. Lung cancer in 2013: refining standard practice and admitting uncertainty. Nat Rev Clin Oncol. 2014;11(2):69–70.CrossRefPubMed

Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95.CrossRefPubMed

Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52.CrossRefPubMed

Barney LE et al. A cell-ECM screening method to predict breast cancer metastasis. Integr Biol (Camb). 2015;7(2):198–212.CrossRef

Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. 2010;11(9):633–43.CrossRefPubMedPubMedCentral

10.

Sung SY et al. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer. 2007;31(2):36–100.CrossRefPubMed

11.

Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–74.CrossRefPubMed

12.

Hoshino D et al. The phosphoinositide-binding protein ZF21 regulates ECM degradation by invadopodia. PLoS One. 2013;8(1), e50825.CrossRefPubMedPubMedCentral

13.

Ohtsuka T et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer. 2006;118(2):263–73.CrossRefPubMed

14.

Arribas J, Bech-Serra JJ, Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev. 2006;25(1):57–68.CrossRefPubMed

15.

Shao S et al. ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer. PLoS One. 2014;9(1), e85936.CrossRefPubMedPubMedCentral

16.

Ishikawa N et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 2004;10(24):8363–70.CrossRefPubMed

17.

Schutz A et al. Expression of ADAM15 in lung carcinomas. Virchows Arch. 2005;446(4):421–9.CrossRefPubMed

18.

Rocks N et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer. 2006;94(5):724–30.PubMedPubMedCentral

19.

O’Shea C et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003;105(6):754–61.CrossRefPubMed

20.

Kveiborg M et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res. 2005;65(11):4754–61.CrossRefPubMed

21.

Lei Y et al. Interaction of LHBs with C53 promotes hepatocyte mitotic entry: a novel mechanism for HBV-induced hepatocellular carcinoma. Oncol Rep. 2012;27(1):151–9.PubMed

22.

Nakada M et al. Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol. 2005;110(3):239–46.CrossRefPubMed

23.

Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.CrossRefPubMedPubMedCentral

24.

Wood SL et al. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.CrossRefPubMed

25.

Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98(5):621–8.CrossRefPubMed

Title: Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer
Authors: Jun Gu
Jie Chen
Jian Feng
Yifei Liu
Qun Xue
Guoxin Mao
Ling Gai
Xiaoning Lu
Rui Zhang
Jialin Cheng
Yanxia Hu
Mengting Shao
Hong Shen
Jianan Huang
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4573-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

FOXC2 is up-regulated in pancreatic ductal adenocarcinoma and promotes the growth and migration of cancer cells

Naive Treg-like CCR7+ mononuclear cells indicate unfavorable prognosis in hepatocellular carcinoma

Doxorubicin nanobubble for combining ultrasonography and targeted chemotherapy of rabbit with VX2 liver tumor

Gastric cardia adenocarcinoma microRNA profiling in Chinese patients

Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients

HPV 16 E7 inhibits OSCC cell proliferation, invasion, and metastasis by upregulating the expression of miR-20a

Keynote webinar | Spotlight on antibody–drug conjugates in cancer